PCK1 and prostate carcinoma: LIF/ZBTB46 axis is a key mechanism for PCK1-driven glucose metabolism, which may bring improvements in prostate cancer treatment after androgen deprivation therapy using PCK1 inhibitors (Liu et al., 2019; Wen et al., 2022).